Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-5,500
Closed -$1.27M 125
2025
Q3
$1.27M Buy
+5,500
New +$1.12M 0.15% 30
2023
Q1
Sell
-3,700
Closed -$598K 7
2022
Q4
$598K Sell
3,700
-39,000
-91% -$5.98M 0.07% 34
2022
Q3
$5.73M Buy
42,700
+8,300
+24% +$1.19M 0.47% 25
2022
Q2
$5.27M Sell
34,400
-29,800
-46% -$4.55M 0.38% 26
2022
Q1
$10.4M Buy
+64,200
New +$9.33M 0.4% 43
2021
Q4
Sell
-36,200
Closed -$3.9M 20
2021
Q3
$3.9M Buy
36,200
+27,300
+307% +$3.12M 0.25% 41
2021
Q2
$1M Buy
8,900
+8,000
+889% +$901K 0.1% 106
2021
Q1
$98K Sell
900
-300
-25% -$32.1K 0.01% 185
2020
Q4
$129K Buy
+1,200
New +$115K 0.01% 90

Other funds holding ABBV

QVR's ABBV Position: Q1 2026 in Review

QVR sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 3,805 shares — an estimated $844K sold.

QVR first reported a position in ABBV in Q4 2020 and held it in 6 quarters. The position peaked at $2.81M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • QVR reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • QVR sold 3,805 AbbVie shares in Q1 2026, an estimated $844K.
  • QVR first reported a position in AbbVie in Q4 2020 and held it in 6 quarters.
  • QVR's AbbVie position peaked at $2.81M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on QVR's 13F filing for Q1 2026, filed 15 Apr 2026.